Login
$TECH
$72.74 -$0.05 (0.07%) After hours

$TECH 4/A SEC Filings

Filed On Filing
02 Nov 2026 Form 4/A: Hippel James, CFO

Received 9,980 shares by exercise or conversion · Gave up 4,423 shares to cover exercise price or tax ($320K) · Disposed of 34,443 Performance Stock Options (Right to Buy) (Disposition to Issuer) · 1 more

02 Nov 2026 Form 4/A: Geist William, PRESIDENT, PROTEIN SCIENCES

Received 6,547 shares by exercise or conversion · Gave up 2,019 shares to cover exercise price or tax ($146K) · Disposed of 22,545 Performance Stock Options (Right to Buy) (Disposition to Issuer) · 1 more

02 Nov 2026 Form 4/A: Kelderman Kim, Director

Received 21,736 shares by exercise or conversion · Gave up 10,955 shares to cover exercise price or tax ($793K) · Disposed of 45,993 Performance Stock Options (Right to Buy) (Disposition to Issuer) · 1 more

02 Nov 2026 Form 4/A: Bohnen Shane, SVP - General Counsel

Received 4,420 shares by exercise or conversion · Gave up 1,366 shares to cover exercise price or tax ($98.9K) · Disposed of 11,929 Performance Stock Option (Right to Buy) (Disposition to Issuer) · 1 more

11 Apr 2025 Form 4/A: Vessey Rupert, Director

Granted 588 Stock Options (Right to Buy)

03 Feb 2025 Form 4/A: McManus Matthew, President - DGS

Granted 15,825 Performance Restricted Stock Units

14 Dec 2023 Form 4/A: Bohnen Shane, SVP - General Counsel

Granted 4,802 Restricted Stock Units · Granted 12,924 Stock Option (Right to Buy)

14 Dec 2023 Form 4/A: Kelderman Kim, Pres. Diagnostics & Genom

Granted 8,873 Restricted Stock Units · Granted 23,881 Stock Options (Right to Buy)

14 Dec 2023 Form 4/A: Hippel James, CFO

Granted 13,865 Restricted Stock Units · Granted 37,314 Stock Options (Right to Buy)

14 Dec 2023 Form 4/A: Geist William, PRESIDENT, PROTEIN SCIENCES

Granted 9,074 Restricted Stock Units · Granted 24,424 Stock Options (Right to Buy)

09 Nov 2023 Form 4/A: Geist William, PRESIDENT, PROTEIN SCIENCES

Granted 19,823 Restricted Stock Units

24 Aug 2023 Form 4/A: Bohnen Shane, SVP - General Counsel

Granted 148 Restricted Stock Units · Granted 16,302 Stock Option (Right to Buy)

29 Sep 2022 Form 4/A: Geist William, President, Protein Sciences

Granted 2,490 Restricted Stock Units

13 Nov 2020 Form 4/A: Hippel James, Chief Financial Officer

Exercised 7,391 Stock Option (Right to Buy)

12 Nov 2020 Form 4/A: Hippel James, Chief Financial Officer

Exercised 8,809 Stock Options (Right to Buy)

20 Aug 2015 Form 4/A: Eansor Norman David, SVP - Novus Biologicals

Granted 9,375 Stock Option (Right to Buy) · Granted 1,500 Restricted Stock Units

20 Aug 2015 Form 4/A: Gavin Robert M., Senior V.P. Protein Platforms

Granted 9,375 Stock Option (Right to Buy) · Granted 1,500 Restricted Stock Units

20 Aug 2015 Form 4/A: Veronneau Marcel, SVP - Clinical Controls

Granted 5,625 Stock Option (Right to Buy) · Granted 900 Restricted Stock Units

20 Aug 2015 Form 4/A: Furlow Brenda S., SVP - General Counsel

Granted 1,200 Restricted Stock Units · Granted 7,500 Stock Option (Right to Buy)

20 Aug 2015 Form 4/A: Kummeth Charles R., Director

Granted 119,275 Stock Option (Right to Buy) · Granted 17,283 Restricted Stock Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support